CSIMarket
 
Glaukos Corp  (GKOS)
Other Ticker:  
 
 
Price: $85.4900 $-0.29 -0.338%
Day's High: $86.29 Week Perf: -1.58 %
Day's Low: $ 84.08 30 Day Perf: -9.75 %
Volume (M): 646 52 Wk High: $ 97.24
Volume (M$): $ 55,184 52 Wk Avg: $70.80
Open: $84.79 52 Wk Low: $45.38



 Market Capitalization (Millions $) 4,141
 Shares Outstanding (Millions) 48
 Employees 900
 Revenues (TTM) (Millions $) 314
 Net Income (TTM) (Millions $) -135
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 20

Glaukos Corp
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.

Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.

Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.

In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.

The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.

Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.


   Company Address: One Glaukos Way Aliso Viejo 92656 CA
   Company Phone Number: 367-9600   Stock Exchange / Ticker: NYSE GKOS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Glaukos Corp

Headline: Glaukos Corp Sees Strong Stock Performance Despite Loss per Share Increase

Glaukos Corp, a leading ophthalmic pharmaceutical and medical technology company, has seen a significant improvement in their stock performance over the past year. The stock has improved by an impressive 87.23%, bringing the share price to a 18.66% increase during the first quarter of 2024. This upward trend in stock performance is further supported by the fact that Glaukos Corp is just 5.9% short off its 52-week high.
Despite this positive stock performance, Glaukos Corp did experience a loss per share of $-0.74 in the most recent fiscal period, compared to $-0.66 a year before. Furthermore, the loss per share has increased from $-0.63 in the prior financial reporting period. However, it's important to note that while the loss per share has widened, the revenue has grown admirably by 15.546% to $82.30 million from $71.23 million in the comparable financial reporting period a year before. Additionally, the revenue has also increased by 6.142% sequentially, from $77.54 million.

Business Update

Glaukos Exceeds Expectations with Preliminary Net Sales of over $81 Million in Q4 2023, Setting the Stage for a Successful Year Ahead

Published Tue, Jan 9 2024 12:00 PM UTC

Aliso Viejo, Calif. ?? Glaukos Corporation (NYSE: GKOS), a leading ophthalmic medical technology and pharmaceutical company specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.With great excitement, Glaukos reveals that their...

Contract

Glaukos Revolutionizes Glaucoma Treatment with FDA Approval of iDose TR and Sets Stage for Promising Growth in the Market

Published Thu, Dec 14 2023 12:00 PM UTC


Glaukos Corporation Receives FDA Approval for iDose TR, Presenting Positive Growth Prospects in the Glaucoma Market
Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, has recently announced the approval of its New Drug Application (NDA) b...

Glaukos Corp

Glaukos Corp's Deficit Strikingly Larger in Q3 2023 Earnings, Raises Questions for Future



Glaukos Corporation, a renowned ophthalmic medical technology and pharmaceutical company, recently released its financial results for the third quarter of 2023. While the company experienced a widening loss per share compared to the same period last year, it witnessed remarkable revenue growth as well as notable increases in inventories and accounts receivable. These results provide valuable insights into Glaukos Corp's performance and offer some indications of how the company may fare in the future.
Losses Per Share and Improved Earnings:
During the third quarter of 2023, Glaukos Corp reported an expanded loss of $-0.63 per share, compared to $-0.58 per share in the same period the previous year. However, there was a positive development, with earnings per share (EPS) improving from $-0.68 in the prior reporting period. While the deepening losses may cause concern, the improvement in EPS signals an upward trend and a potential turnaround in the near future.

Glaukos Corp

Glaukos Corp: Second Quarter of 2023 Sees Spectacular Rise in Revenue and Decrease in Losses

Glaukos Corp, a leading company in the medical equipment and supplies industry, has reported positive financial results for the second quarter of 2023. Despite the seasonal nature of its business, the company has shown impressive growth in revenue and a decrease in net deficit.
In terms of earnings per share, Glaukos Corp managed to decrease its loss from $0.96 per share in the same quarter last year to $0.68 per share. Additionally, its income per share improved from $0.72 per share in the previous quarter. These figures demonstrate the company's commitment to improving its financial performance.






 

Glaukos's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Glaukos does not provide revenue guidance.

Earnings Outlook
Glaukos Corp does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com